Ceribell, Inc. (CBLL) stock intrinsic value fair value estimate & owner earnings analysis

Ceribell makes a rapid-response EEG system for hospital intensive care units and emergency departments. A nurse can place its disposable headband (the Wearable) on a patient in minutes, and the Clarity AI software watches the brain signal for seizures and alerts clinicians, without waiting for an EEG technician or a neurologist. The company earns money two ways, and both repeat: it sells a single-use headband for each patient, and it charges hospitals a monthly subscription for the recorder, the Clarity software and the portal. Nearly all sales are to US hospitals. It went public on Nasdaq in October 2024 at $17.00 a share, raising $187.8 million. The product is selling well. Revenue went from $45.2 million in 2023 to $65.4 million in 2024 and $89.1 million in 2025, and it was up 31% in the first half of 2026 ($54.6 million). Gross margin is very high at about 88-90%. The business case depends on what the company spends to get that growth. In the first half of 2026 it spent $46.8 million on sales and marketing, $30.1 million on general and administrative costs and $12.9 million on research, against $49.1 million of gross profit. The operating loss was $40.7 million, up from $29.2 million a year earlier. Losses have grown faster than revenue: they were about 61% of revenue in 2024, 66% in 2025 and 75% in the first half of 2026. The company has told investors it expects to keep losing money for the foreseeable future. How we measured earnings. We start from operating cash flow. We take out working-capital timing swings. We charge stock compensation as a real cost ($12.2 million in 2025, $9.7 million in the first half of 2026). We also deduct the capital spending needed to keep the business running, and we count recorders placed with hospitals as part of that spending. On that basis the owners lost about $29.9 million in 2023, $38.3 million in 2024 and $54.6 million in 2025. The first half of 2026 lost about $39.8 million, roughly $80 million a year. Before interest, the loss was about $52.7 million in 2025 and is running near $77.8 million a year now. Both quarters of 2026 are at this higher level, so we use it as the starting point rather than the lower three-year median. Losses grew about 45% in 2025, and none of our cases assumes they shrink from here on their own. Why no growth or future profit is credited. We only count growth that is locked in or that the company has shown it can repeat over many years, through a downturn, and pay for itself. Ceribell's growth has run for only a few years. It has been paid for with IPO and loan money, and it depends on winning new hospitals and more use per hospital. Getting to profit would also need a major change in spending. Management has not announced such a change, and the filings do not show it happening. We checked whether the existing customer base could support the company if selling stopped. In the first half of 2026, gross profit of $49.1 million only just covered research plus general and administrative costs of $43.0 million, before any selling or clinical support. At today's cost structure, even a no-growth version of the business would barely break even. For that reason we give no value to earnings beyond what the cash on hand pays for. This is the most important judgement in the analysis, and it is the main reason our estimate is well below a valuation that credits future growth. Balance sheet. At June 30, 2026, Ceribell held $129.3 million of cash and marketable securities. It owes a $20.0 million term loan from SVB and Horizon, which costs about 9.5% a year including its end-of-term fee. The loan is repaid in twelve monthly payments from April 2028 to March 2029, with $15.0 million due in 2028 and $5.0 million in 2029. The loan agreement includes financial covenants on net debt and on revenue-based ratios. Because the interest rate is well above our 6% rate, we count the loan as about $21.5 million. At the current burn, the cash lasts about 20 months, which runs out close to when loan repayments begin. The company's own filing only says its cash covers at least the next 12 months. Bear case (about -$0.40 a share). The company keeps losing cash at the first-half-2026 pace until the money is gone, in early 2028, just before the loan starts to amortize. It then has to raise money or restructure on terms that leave current shareholders nothing more. The business is worth about -$123 million, the present value of the cash it uses up. It holds $129.3 million of cash and owes about $21.5 million, which leaves roughly -$15 million. On what we can credit, the company would owe about $15 million more than it is worth. In practice the value of its hospital customer base would decide whether lenders are fully repaid. Base case (about $0.84 a share). The company keeps losing cash at the current pace for the 12 months its own funding statement covers. After that it either raises new money on fair terms or cuts spending to what the customer base supports, so current owners' cash stops being consumed. The business is worth about -$76 million, it holds $129.3 million of cash and owes about $21.5 million, which leaves about $32 million. Bull case (about $1.48 a share). Strong revenue growth at 89-90% gross margins brings the cash loss back to the 2025 level of about $52.7 million a year before interest, instead of $77.8 million. The company changes course after the same 12 months. The business is worth about -$51 million, it holds $129.3 million of cash and owes about $21.5 million, which leaves about $57 million. What would make this wrong. The company would be worth much more if it showed that operating losses can shrink while it keeps growing. That would mean several quarters in which sales and administrative costs grow more slowly than gross profit, or a real move toward break-even that can be checked in the filings. It would be worth less if spending rises again or cash runs short before a financing is arranged. Ceribell is also suing Natus to protect its headband patents, including a case at the US International Trade Commission. That case protects the product but costs money, and we give it no value either way. We could not see any financing or spending decisions made after June 30, 2026.